Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3236864 | 0.98 | ALDH1A1 (0.48) | ALDH1A1TDP1SMN1; SMN2EPHX1SPHK1 | |
| SCHEMBL29593 | 0.98 | ALDH1A1 (0.48) | ALDH1A1TDP1SMN1; SMN2EPHX1SPHK1 | |
| SCHEMBL2485850 | 0.98 | ALDH1A1 (0.48) | ALDH1A1TDP1SMN1; SMN2EPHX1SPHK1 | |
| SCHEMBL3245975 | 0.98 | ALDH1A1 (0.48) | ALDH1A1TDP1SMN1; SMN2EPHX1SPHK1 | |
| SCHEMBL3241128 | 0.98 | ALDH1A1 (0.48) | ALDH1A1TDP1SMN1; SMN2EPHX1SPHK1 | |
| SCHEMBL3231987 | 0.98 | ALDH1A1 (0.48) | ALDH1A1TDP1SMN1; SMN2EPHX1SPHK1 | |
| SCHEMBL3241157 | 0.98 | ALDH1A1 (0.48) | ALDH1A1TDP1SMN1; SMN2EPHX1SPHK1 | |
| SCHEMBL3241159 | 0.98 | ALDH1A1 (0.48) | ALDH1A1TDP1SMN1; SMN2EPHX1SPHK1 | |
| SCHEMBL3238846 | 0.94 | ALDH1A1 (0.50) | ALDH1A1TDP1SMN1; SMN2EPHX1 | |
| SCHEMBL2486232 | 0.90 | ALDH1A1 (0.56) | ALDH1A1TDP1SMN1; SMN2EPHX1SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177639-A1 | LATENT CURING CATALYSTS AND RESIN COMPOSITION CONTAINING THE SAME | NAMICS CORPORATION (JP) | 2022-06-09 | — | — | US | disclosed |
| EP-3967729-A1 | LATENT CURING CATALYST AND RESIN COMPOSITION CONTAINING SAME | Namics Corporation (JP) | 2022-03-16 | — | — | EP | disclosed |
| US-6646093-B2 | Extruding auxiliary for cement materials, a mortar thickening agent, an underwater concrete thickening agent, a ceramics forming binder and a moisturizer for hair cosmetics; water and shape retention. | MITSUI CHEMICALS, INC. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-6515050-B1 | An extruding auxiliary using the above novel water-soluble polyurethane; additive for underwater concrete | MITSUI CHEMICALS, INC. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020045724-A1 | Water-souluble polyurthane having comb-shaped hydrophobic group and application thereof | MITSUI TAKEDA CHEMICALS, INC. (JP) | 2002-04-18 | — | — | US | disclosed |
| EP-1184364-A1 | COMB-SHAPED DIOL, WATER-SOLUBLE POLYURETHANE, AND USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-03-06 | — | — | EP | disclosed |
| US-4160741-A | Benzothiazole accelerators stabilized with oxirane compounds | AMERICAN CYANAMID COMPANY (US) | 1979-07-10 | — | — | US | disclosed |
| US-4129452-A | WITH AN OXIRANE | AMERICAN CYANAMID COMPANY (US) | 1978-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045724-A1 | Water-souluble polyurthane having comb-shaped hydrophobic group and application thereof | BMI1, ASH2L, HAT1 | ALDH1A1 804/4885TDP1 3094/4885SMN1; SMN2 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.